RT Journal Article
T1 COVID-19 prevalence and mortality in people with epilepsy: A nation-wide multicenter study
A1 Sanchez-Larsen, Alvaro
A1 Conde-Blanco, Estefania
A1 Viloria-Alebesque, Alejandro
A1 Sanchez-Vizcaino Buendia, Cristina
A1 Espinosa Oltra, Tatiana
A1 Alvarez-Noval, Amanda
A1 Aledo-Serrano, Angel
A1 Martin-Garcia, Raquel
A1 Ramos-Araque, Maria E.
A1 Campos, Dulce
A1 Valle-Penacoba, Gonzalo
A1 Sierra-Gomez, Alicia
A1 De Ceballos-Cerrajeria, Pablo
A1 Agundez-Sarasola, Marta
A1 Khawaja, Mariam
A1 Hampel, Kevin G.
A1 Serra-Martinez, Maria
A1 Arbos-Barber, Clara
A1 Gomez-Ibanez, Asier
A1 Villino-Boquete, Rafael
A1 Cabezudo-Garcia, Pablo
A1 Rodriguez-Lavado, Ignacio
A1 Principe, Alessandro
A1 Sopelana-Garay, David
K1 COVID-19
K1 Coronavirus SARS-CoV-2
K1 Prevalence
K1 Epilepsy
K1 Seizures
K1 Ilae commission
K1 Position paper
K1 Classification
AB Background: To assess the prevalence, severity, and mortality of COVID-19 in people with epilepsy (PWE) and evaluate seizure control in PWE during and after COVID-19. Methods: Retrospective, observational, multicenter study conducted in 14 hospitals. Medical records of randomly selected PWE followed at neurology outpatient clinics were reviewed. Proportion of PWE with a positive test for SARS-CoV-2 during 2020 was calculated. Risk factors associated with COVID-19 and its morbimortality were evaluated. Results: 2751 PWE were included, mean age 48.8 years (18-99), 72.4% had focal epilepsy, and 35% were drug-refractory. COVID-19 prevalence in PWE was 5.53%, while in the Spanish population was 4.26%. Proportion of admissions to hospital, ICU, and deaths in PWE were 17.1%, 2%, and 4.61% of COVID-19 cases, while in Spanish population were 10.81%, 0.95%, and 2.57%, respectively. A severe form of COVID-19 occurred in 11.8%; dyslipidemia, institutionalization at long-term care facilities, intellectual disability, and older age were associated risk factors. Older age, hypertension, dyslipidemia, cardiac disease, and institutionalization were associated with mortality from COVID-19. Seizure control was stable in 90.1% of PWE during acute COVID-19, while 8.6% reported an increase in seizure frequency. During post-COVID-19 follow-up, 4.6% reported seizure control worsening.
PB Academic press inc elsevier science
SN 1525-5050
YR 2021
FD 2021-10-29
LK https://hdl.handle.net/10668/24532
UL https://hdl.handle.net/10668/24532
LA en
DS RISalud
RD Apr 17, 2025